GenDx联合创始人Wietse Mulder向AI移植公司Immunomatics投资10万美元，并出任战略顾问-动脉网

GenDx Co-Founder Wietse Mulder Invests $100,000 in AI Transplant Company Immunomatics and Joins as Strategic Advisor

CISION 等信源发布 2026-10-07 20:41



可切换为仅中文







Experienced transplant diagnostics entrepreneur adds strategic backing and industry guidance to Immunomatics and its AI-based approach to transplant donor risk assessment

经验丰富的移植诊断领域企业家为 Immunomatics 及其基于人工智能的移植供体风险评估方法提供战略支持和行业指导

SAN MARCOS, Calif.

加利福尼亚州圣马科斯

，

Oct. 7, 2026

2026年10月7日

/PRNewswire/ -- Immunomatics, Inc., a healthtech company developing AI-based tools to improve transplant donor-recipient risk assessment, today announced a

/美通社/ -- Immunomatics, Inc. 是一家开发基于人工智能的工具以改善移植供体-受体风险评估的健康科技公司，该公司今日宣布

$100,000 strategic investment from Myosotis Investments B.V.

来自 Myosotis Investments B.V. 的 10 万美元战略投资

, a Netherlands-based life sciences investment firm founded by biotech entrepreneur

，一家由生物技术企业家创立、总部位于荷兰的生命科学投资公司

Wietse Mulder, PhD

维特塞·穆尔德，博士

. Mulder has also joined Immunomatics as Strategic Advisor.

穆尔德也已加入Immunomatics，担任战略顾问。

The investment and advisory role are strategically significant to Immunomatics, given Mulder's experience in HLA and transplantation. He co-founded GenDx, a global leader in transplant diagnostics acquired by Eurobio Scientific in 2022. As Strategic Advisor, Mulder will leverage his experience to guide Immunomatics as it validates its technology and prepares for commercialization..

鉴于穆尔德在HLA和移植领域的经验，其投资与顾问角色对Immunomatics具有战略意义。他联合创立了GenDx，该公司是移植诊断领域的全球领导者，于2022年被Eurobio Scientific收购。作为战略顾问，穆尔德将利用其经验，在Immunomatics验证其技术并为商业化做准备的过程中提供指导。

'Wietse spent nearly two decades building a globally recognized company in HLA and transplant diagnostics,'

“维特瑟花了近二十年时间，在HLA和移植诊断领域打造了一家全球知名的公司。”

said Lidio Meireles, PhD, founder and CEO of Immunomatics.

Immunomatics 公司创始人兼首席执行官 Lidio Meireles 博士表示。

'He understands the science, the clinical environment, and what it takes to bring new transplant technologies to market. Having someone with that experience invest in Immunomatics and join us as a strategic advisor is a tremendous validation of the opportunity we are pursuing.'

“他深谙科学原理、临床环境，以及将新型移植技术推向市场所需的关键要素。这样一位富有经验的人士投资 Immunomatics 并担任我们的战略顾问，是对我们所 pursued 机遇的巨大肯定。”

'Immunomatics is addressing an important challenge in transplantation: how to make better use of increasingly complex biological and clinical information when assessing donor-recipient compatibility,'

“Immunomatics 正在应对移植领域的一个重要挑战：如何在评估供体-受体相容性时，更好地利用日益复杂的生物和临床信息。”

said Wietse Mulder, PhD, founder of Myosotis Investments.

Myosotis Investments 创始人、哲学博士 Wietse Mulder 表示。

'Lidio brings a rare combination of computational expertise, scientific understanding, and personal experience as a transplant recipient. I believe there is a significant opportunity to develop better predictive tools that can support transplant medicine, and I am pleased to support Immunomatics as both an investor and strategic advisor as it advances this work.'.

“Lidio 兼具计算专业知识、科学理解力以及作为移植受体的亲身经历，这种组合十分罕见。我相信，在开发能够更好地支持移植医学的预测工具方面存在重大机遇，我很高兴以投资者和战略顾问的身份支持 Immunomatics 推进这项工作。”

Immunomatics is developing AI to improve transplant compatibility assessment beyond counting HLA mismatches. Using outcomes data, HLA typing, and machine learning, it aims to better estimate donor-recipient risks and support transplant teams' clinical decision-making. Founder Meireles, a computational biologist with biotech experience, started Immunomatics after facing donor-selection uncertainty as a blood stem cell recipient, with limited tools to choose the lowest-risk donor..

Immunomatics 正在开发人工智能技术，以改进移植相容性评估，突破仅依靠计算 HLA 错配数量的局限。该公司利用预后数据、HLA 分型以及机器学习，旨在更准确地评估供体与受体之间的风险，并支持移植团队的临床决策。创始人梅雷莱斯（Meireles）是一位拥有生物技术经验的计算生物学家，他在作为造血干细胞受体者面临供体选择不确定性、且缺乏有效工具来选择最低风险供体的情况下，创立了 Immunomatics。

The company has received a

该公司已收到

$207,740 NIH SBIR Phase I award

207,740美元美国国立卫生研究院小企业创新研究计划第一阶段资助

to advance its technology and is collaborating with the

以推进其技术，并正在与

UC San Diego Transplantation Lab.

加州大学圣地亚哥分校移植实验室

Immunomatics is now working to expand its clinical data, validate its models, advance its regulatory strategy, and prepare its technology for future clinical use.

Immunomatics 目前正致力于扩大其临床数据、验证其模型、推进其监管策略，并为其技术在未来临床应用方面做好准备。

The Myosotis investment and Mulder's appointment as Strategic Advisor add to Immunomatics' growing momentum as the company raises capital to accelerate validation and commercialization of its technology. Immunomatics is also conducting an equity crowdfunding campaign on Wefunder, offering individual investors the opportunity to invest in the company..

Myosotis 的投资以及 Mulder 被任命为战略顾问，进一步增强了 Immunomatics 日益强劲的发展势头；该公司正在筹集资金，以加速其技术的验证和商业化进程。此外，Immunomatics 还在 Wefunder 平台上开展股权众筹活动，为个人投资者提供投资该公司的机会。

Learn more about the offering:

了解更多关于该产品的信息：

https://wefunder.com/immunomatics

About Immunomatics

关于免疫信息学

Immunomatics, Inc. is a healthtech company developing AI-based tools to improve donor-recipient compatibility risk assessment in solid organ and blood stem cell transplantation. By integrating HLA information, transplant outcomes, and machine learning, the company aims to support better-informed donor selection and more personalized transplant care..

Immunomatics, Inc. 是一家健康科技公司，致力于开发基于人工智能的工具，以改善实体器官和血液干细胞移植中供体-受体相容性风险评估。通过整合 HLA 信息、移植结果和机器学习技术，该公司旨在支持更明智的供体选择，并提供更加个性化的移植护理。

About Myosotis Investments B.V.

关于 Myosotis Investments B.V.

Myosotis Investments was founded in 2024 by Dr. Wietse Mulder and is based in Zeist, The Netherlands. The firm supports organizations that have a mission-driven approach aiming to impact healthcare leading to better care of patients. The firm focuses on advancements in molecular diagnostics and life sciences.

Myosotis Investments 由 Wietse Mulder 博士于 2024 年创立，总部位于荷兰 Zeist。该公司支持那些以使命为导向、旨在改善医疗保健并提升患者护理质量的组织。公司专注于分子诊断和生命科学领域的进展。

Their current portfolio includes innovative companies such as Idevax B.V., Kairos Biotech Ltd, Cyclomics B.V., Tzu Cancer Therapeutics B.V., PamDx, and Scinus Cell Expansion B.V..

他们当前的投资组合包括多家创新企业，例如 Idevax B.V.、Kairos Biotech Ltd、Cyclomics B.V.、Tzu Cancer Therapeutics B.V.、PamDx 以及 Scinus Cell Expansion B.V.。

More information:

更多信息：

www.myosotisinvestments.com

领英

Media Contact

媒体联系人

Immunomatics, Inc.

免疫自动学公司

Lidio Meireles, PhD

利迪奥·梅雷莱斯，博士

Founder & CEO